Search Results

Eli Lilly and Co.’s frustrating attempt to get a ruling from federal regulators on its experimental blood thinner prasugrel may be a test case of life under a more cautious-and understaffed-U.S. Food and Drug Administration. That’s the opinion taken by many pharmaceutical analysts after the FDA missed its self-imposed Sept. 26 deadline to make a ruling on prasugrel. The FDA already had delayed its decision by three months after it agreed to give prasugrel a “priority” review lasting six months….

Eli Lilly and Co.’s planned acquisition of ImClone Systems Inc. is its boldest move yet to replace revenue it will lose once patent coverage for its bestseller Zyprexa expires in three years. The Indianapolis-based drugmaker announced this morning it would pay $6.5 billion in cash to acquire New York-based ImClone, a biotech firm that develops […]

Wall Street didn’t embrace Eli Lilly and Co. CEO John Lechleiter’s plan to acquire biotech firm ImClone Systems Inc., a maker of cancer drugs, for $6.5 billion. Lilly shares tumbled 5 percent today to less than $40 a share-a new 52-week low. One analyst called Lilly’s deal “an act of desperation” as the company struggles […]

Eli Lilly and Co. promised to dole out $62 million to 32 states to settle claims that the Indianapolis drugmaker improperly marketed its bestselling drug, the antipsychotic Zyprexa. Indiana will get $1.6 million of the total, according to Attorney General Steve Carter. Attorneys general from the 32 states had claimed that Lilly illegally promoted Zyprexa […]

Eli Lilly and Co.‘s settlement of Zyprexa litigation sent it to a $466 million loss during its third quarter. But the Indianapolis-based drugmaker exceeded expectations of Wall Street analysts. Lilly spent nearly $1.5 billion to settle a 32-state probe into its marketing and disclosures about Zyprexa, an antipsychotic that is the company’s bestselling drug. It […]